365 related articles for article (PubMed ID: 29035832)
1. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
Zhang Y; Yang SH; Guo XL
Biomed Pharmacother; 2017 Dec; 96():659-666. PubMed ID: 29035832
[TBL] [Abstract][Full Text] [Related]
2. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
Pereira E; Tarasiuk J; Garnier-Suillerot A
Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
5. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
6. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
Kavallaris M; Tait AS; Walsh BJ; He L; Horwitz SB; Norris MD; Haber M
Cancer Res; 2001 Aug; 61(15):5803-9. PubMed ID: 11479219
[TBL] [Abstract][Full Text] [Related]
7. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
Gan PP; Kavallaris M
Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class.
Owellen RJ; Hartke CA; Dickerson RM; Hains FO
Cancer Res; 1976 Apr; 36(4):1499-502. PubMed ID: 1260766
[TBL] [Abstract][Full Text] [Related]
9. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
[TBL] [Abstract][Full Text] [Related]
10. [Properties of antitumor activity of vinorelbine tartrate, a new vinca alkaloid antitumor agent].
Kanazawa J; Morimoto M; Ohmori K
Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):215-23. PubMed ID: 11084918
[TBL] [Abstract][Full Text] [Related]
11. Novel aspects of natural and modified vinca alkaloids.
Duflos A; Kruczynski A; Barret JM
Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):55-70. PubMed ID: 12678751
[TBL] [Abstract][Full Text] [Related]
12. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
Lobert S; Vulevic B; Correia JJ
Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
[TBL] [Abstract][Full Text] [Related]
13. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
Lobert S; Frankfurter A; Correia JJ
Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical pharmacology of vinca alkaloids.
Zhou XJ; Rahmani R
Drugs; 1992; 44 Suppl 4():1-16; discussion 66-9. PubMed ID: 1283846
[TBL] [Abstract][Full Text] [Related]
16. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
[TBL] [Abstract][Full Text] [Related]
18. Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids.
Attaoua C; Vincent LA; Abdel Jaoued A; Hadj-Kaddour K; Baï Q; De Vos J; Vian L; Cuq P
Fundam Clin Pharmacol; 2015 Feb; 29(1):62-71. PubMed ID: 25283245
[TBL] [Abstract][Full Text] [Related]
19. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
[TBL] [Abstract][Full Text] [Related]
20. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
Zhang CC; Yang JM; Bash-Babula J; White E; Murphy M; Levine AJ; Hait WN
Cancer Res; 1999 Aug; 59(15):3663-70. PubMed ID: 10446979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
